Jenapri Pr

Dipyridamole, the active ingredient in Jenapri Pr, is a phosphodiesterase inhibitor presented as an oral dosage form for oral use. It is employed to reduce platelet aggregation and to help prevent thromboembolic events in patients at risk, including those with a history of transient ischemic attack or ischemic stroke.

GNH USA supplies Jenapri Pr as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Dipyridamole acts on platelet function and vascular tone, making it useful in several cardiovascular contexts.

- Prevention of thromboembolic events: lowers the risk of clot formation in at‑risk patients. - Secondary prevention after transient ischemic attack (TIA) or ischemic stroke: helps reduce recurrence of cerebrovascular events. - Adjunct therapy in coronary artery disease: used alongside other agents to improve myocardial perfusion and reduce ischemic complications.

Dipyridamole may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache - Dizziness - Nausea - Flushing - Abdominal discomfort - Diarrhea

Serious or Rare Side Effects: - Severe bleeding - Thrombocytopenia - Hypersensitivity reactions (rash, angioedema) - Elevated liver enzymes - Neutropenia - Cardiac arrhythmias

When prescribing dipyridamole, clinicians should consider several safety aspects.

- Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic disease: use with caution; periodic liver function tests are advisable. - Concomitant anticoagulants: increased risk of bleeding; close monitoring required. - Pregnancy: safety not established; avoid unless benefits outweigh risks. - Surgery or invasive procedures: discontinue before elective operations to reduce bleeding risk. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Dipyridamole can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Warfarin: potentiates anticoagulant effect, increasing bleeding risk. - Heparin: additive anticoagulation may lead to severe hemorrhage. - Clopidogrel: combined antiplatelet action can cause excessive bleeding.

Moderate Interactions (Monitor Closely): - Aspirin: may enhance bleeding tendency. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase gastrointestinal bleeding risk. - Beta‑blockers: may blunt dipyridamole‑induced vasodilation, affecting therapeutic response.